Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) announced this morning that the company has received regulatory approval from the Polish Ministry of Health to begin distributing medicinal cannabis product to their country. In conjunction with their wholly-owned subsidiary, Aurora Deutschland GmbH, Aurora Cannabis will begin shipments to a treatment centers and hospitals to the capital of Warsaw.
Aurora Deutschland GmbH compiles with EU GMP standards just like every one of the other Aurora Cannabis’s facilities. Poland allows the distribution of cannabis to patients throughout the country if a licensed physician prescribes them a prescription for it first. Cannabis can even be prescribed through a registered pharmacy to patients. This is the first time that any public cannabis company has been approved to send cannabis derived product to Poland.
Aurora Cannabis recently made its debut on the New York Stock Exchange but, its debut was nothing to celebrate. The company’s stock fell 8% after moving from the OTCQB to the NYSE yet, their trading volume was the 7th highest on the stock exchange at 30 million shares.
“Becoming the first company to supply cannabis to Poland is validation of Aurora’s ability to do business in international markets with high barriers to entry. This is an important milestone for patient access in Poland, which will provide options for people seeking alternative medications to help manage symptoms of a wide range of medical conditions.
Aurora continues to grow its international footprint, which now spans 19 countries on five continents, and puts us in an enviable position to capitalize on our early mover advantage,” Neil Belot, Chief Global Business Development Officer of Aurora Cannabis said in the press release.